Equities research analysts predict that Moderna, Inc. (NASDAQ:MRNA – Get Rating) will post $4.63 billion in sales for the current quarter, according to Zacks. Seven analysts have made estimates for Moderna’s earnings, with estimates ranging from $2.24 billion to $6.02 billion. Moderna posted sales of $1.94 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 138.7%. The business is expected to issue its next earnings results before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Moderna will report full-year sales of $22.14 billion for the current financial year, with estimates ranging from $19.57 billion to $25.86 billion. For the next fiscal year, analysts expect that the business will post sales of $10.74 billion, with estimates ranging from $3.99 billion to $17.02 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Moderna.
Moderna (NASDAQ:MRNA – Get Rating) last announced its earnings results on Thursday, February 24th. The company reported $11.29 earnings per share for the quarter, beating the consensus estimate of $9.83 by $1.46. The company had revenue of $7.21 billion during the quarter, compared to the consensus estimate of $6.73 billion. Moderna had a return on equity of 140.21% and a net margin of 66.06%. The company’s revenue was up 1163.3% on a year-over-year basis. During the same period last year, the firm earned ($0.69) earnings per share.
In other news, CEO Stephane Bancel sold 9,000 shares of Moderna stock in a transaction that occurred on Wednesday, February 23rd. The stock was sold at an average price of $144.60, for a total transaction of $1,301,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Juan Andres sold 2,000 shares of Moderna stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $184.66, for a total value of $369,320.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 208,054 shares of company stock valued at $33,815,814. 17.30% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. Stokes Family Office LLC raised its holdings in Moderna by 8.2% during the third quarter. Stokes Family Office LLC now owns 1,162 shares of the company’s stock worth $447,000 after purchasing an additional 88 shares in the last quarter. Horizon Investments LLC bought a new stake in Moderna during the third quarter worth approximately $2,137,000. Arrowstreet Capital Limited Partnership bought a new stake in Moderna during the third quarter worth approximately $159,563,000. LPL Financial LLC raised its holdings in Moderna by 19.3% during the third quarter. LPL Financial LLC now owns 150,061 shares of the company’s stock worth $57,753,000 after purchasing an additional 24,239 shares in the last quarter. Finally, First Republic Investment Management Inc. raised its holdings in Moderna by 10.9% during the third quarter. First Republic Investment Management Inc. now owns 98,867 shares of the company’s stock worth $38,050,000 after purchasing an additional 9,679 shares in the last quarter. 60.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Moderna stock opened at $140.34 on Friday. The business has a 50-day moving average of $157.26 and a 200-day moving average of $220.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.76 and a quick ratio of 1.60. The company has a market capitalization of $56.56 billion, a PE ratio of 4.96, a P/E/G ratio of 0.94 and a beta of 1.55. Moderna has a 1-year low of $122.01 and a 1-year high of $497.49.
About Moderna (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.